RARECast
Een podcast door RARECast - Donderdagen
548 Afleveringen
-
How One Drugmaker Reaches out to Communities at Greater Risk for Rare Heart Condition
Gepubliceerd: 3-3-2023 -
A Next-Generation RNA Therapy Targets Telomere Disorders
Gepubliceerd: 3-3-2023 -
BridgeBio Advances Therapy for Limb-Girdle Muscular Dystrophy that Started with Two Patient Families
Gepubliceerd: 24-2-2023 -
Translating Urgency into Science
Gepubliceerd: 16-2-2023 -
Empowering Ultra-Rare Disease Patients to Pursue the Discovery of Treatments
Gepubliceerd: 10-2-2023 -
Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X
Gepubliceerd: 2-2-2023 -
An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty
Gepubliceerd: 26-1-2023 -
Powering Cells in People with Rare Mitochondrial Diseases
Gepubliceerd: 19-1-2023 -
Powering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapy
Gepubliceerd: 12-1-2023 -
Developing a New Class of Therapies Based on a Natural Cargo Carrier
Gepubliceerd: 5-1-2023 -
Reaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies
Gepubliceerd: 29-12-2022 -
One Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia
Gepubliceerd: 22-12-2022 -
Treating Rare Endocrine Disorders with Therapeutic Peptides
Gepubliceerd: 15-12-2022 -
Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases
Gepubliceerd: 8-12-2022 -
Addressing the Current Limitations of AAV Gene Therapies
Gepubliceerd: 1-12-2022 -
Examining the Legislative Landscape for Rare Disease Drug Development
Gepubliceerd: 24-11-2022 -
How a Drug Setback Became a Patient Community’s Gain
Gepubliceerd: 18-11-2022 -
Helping Regulators and Drug Developers Understand the Challenges of Living with Fabry Disease
Gepubliceerd: 10-11-2022 -
Addressing Racial Disparities in a Rare Blood Cancer
Gepubliceerd: 3-11-2022 -
How New Sequencing Technology Promises to Alter the Diagnostic Odyssey
Gepubliceerd: 27-10-2022
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.
